Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy –– ARV-102 ...
Medical Xpress

Study finds the timing of CSF biomarker divergence for Alzheimer disease, normal cognition varies

Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before ...
Seeking Alpha

Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys ® Total-Tau CSF assays (tTau) have received U.S. Food and Drug ...
Medscape

Alzheimer’s Disease Leaves Signature in Blood and CSF

OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...
The Scientist

Cerebrospinal Fluid Reflects Disease-Specific Immune Profiles

Using single-cell sequencing, researchers found distinct immune profiles in different CNS tumors, highlighting its potential as a prognostic tool.